# Clinical Translational Research Core

> **NIH NIH P30** · JOSLIN DIABETES CENTER · 2021 · $166,098

## Abstract

CORE 3 - CLINICAL TRANSLATIONAL RESEARCH CORE (CTRC): ABSTRACT 
The objective of the Clinical Translational Research Core (CTRC) is to facilitate high-quality clinical 
translational research specifically applicable to the understanding, prevention and treatment of diabetes, its 
complications, and related metabolic disorders. Research supported by the CTRC will leverage use of core 
facilities and faculty with expertise in a broad range in clinical research methods, from proof of concept and 
physiology, to clinical trials or comparative effectiveness studies to support the more than 35 Principal 
Investigators doing clinical research at Joslin. The CTRC will support the bi-directional journey of discovery 
from molecule, to model, to man, and back, while serving as the bridge between clinical observation, bench, 
and human investigation in adult and pediatric patients. Joslin has invested in new facilities for the Clinical 
Research Center which will serve as the infrastructure for the new DRC core. These facilities include exercise 
training and testing capacities, infusion and procedure rooms for adult and pediatric volunteers, and laboratory 
processing and biobanking facilities for valuable human specimens. We have well-trained nursing and 
technical staff to perform gold standard euglycemic, hyperglycemic, and hypoglycemic clamps at physiologic or 
pharmacologic insulin concentrations; intravenous and oral glucose and mixed meal tolerance tests; and other 
metabolic testing to assess insulin secretion, insulin action, and other metabolic processes for patient centered 
research specific to diabetes. Specific aims of the new core are to 1) enable proof-of-concept and first-in-man 
“T1” translational research programs with specific focus on Prediction, Prevention, and Interdiction of type 1 
(T1DM) and type 2 diabetes (T2DM) and related complications; 2) facilitate design, implementation, and 
evaluation of investigator-initiated clinical trials and observational studies for translation to patients in “T2-T3” 
research programs focused on improving and optimizing treatments of T1DM or T2DM and related 
complications; and 3) generate and maintain a registry of and a diabetes-specific biorepository of samples from 
our unique Joslin cohorts of patients with unusual phenotypes that have been extensively characterized. To 
achieve these aims the CTRC will provide an integrated and efficient core to support collaborative, 
multidisciplinary diabetes clinical research with services that include: a) consultation services, training, and 
mentoring of Investigators and fellows in methods and regulatory processes specific to human investigation; b) 
expert professional and technical help in the development and execution of protocols specific to diabetes and 
the complex assessments of glycemia, insulin secretion, insulin action, and exercise; c) support for 
biospecimen samples and data management; and d) guidance for analysis and interpretation of da...

## Key facts

- **NIH application ID:** 10160878
- **Project number:** 5P30DK036836-35
- **Recipient organization:** JOSLIN DIABETES CENTER
- **Principal Investigator:** LORI M LAFFEL
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $166,098
- **Award type:** 5
- **Project period:** 1997-02-15 → 2022-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10160878

## Citation

> US National Institutes of Health, RePORTER application 10160878, Clinical Translational Research Core (5P30DK036836-35). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10160878. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*